FibroGen

FibroGen

FibroGen

FibroGen, a research-based biotech firm, uses its expertise CTGF and HIF biologyto discover, develop, and commercialize novel therapeutics.
Founded
1993
Raised
$182M
Follow us
Alexa global traffic share
Latest funding Show all
$62,000,000
Post-IPO equity - 2016
AstraZeneca
$20,000,000
Venture capital - 2014
Team Size
200+
Employees
Xconomy

FibroGen Pushes Forward With Anemia Pill in China, But Big Test Awaits

Health Science
$62,000,000 Post-IPO equity
biospace

FibroGen Gets 62 Million License Payment from Partner AstraZeneca PLC

Health Science